GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » Current Ratio

HCW Biologics (HCW Biologics) Current Ratio : 0.73 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. HCW Biologics's current ratio for the quarter that ended in Dec. 2023 was 0.73.

HCW Biologics has a current ratio of 0.73. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If HCW Biologics has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for HCW Biologics's Current Ratio or its related term are showing as below:

HCWB' s Current Ratio Range Over the Past 10 Years
Min: 0.73   Med: 11.53   Max: 17.43
Current: 0.73

During the past 5 years, HCW Biologics's highest Current Ratio was 17.43. The lowest was 0.73. And the median was 11.53.

HCWB's Current Ratio is ranked worse than
87.52% of 1554 companies
in the Biotechnology industry
Industry Median: 3.77 vs HCWB: 0.73

HCW Biologics Current Ratio Historical Data

The historical data trend for HCW Biologics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HCW Biologics Current Ratio Chart

HCW Biologics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
7.53 12.14 17.43 11.53 0.73

HCW Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.53 6.62 4.36 2.56 0.73

Competitive Comparison of HCW Biologics's Current Ratio

For the Biotechnology subindustry, HCW Biologics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HCW Biologics's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's Current Ratio distribution charts can be found below:

* The bar in red indicates where HCW Biologics's Current Ratio falls into.



HCW Biologics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

HCW Biologics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=6.404/8.748
=0.73

HCW Biologics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=6.404/8.748
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HCW Biologics  (NAS:HCWB) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


HCW Biologics Current Ratio Related Terms

Thank you for viewing the detailed overview of HCW Biologics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


HCW Biologics (HCW Biologics) Business Description

Traded in Other Exchanges
N/A
Address
2929 N Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company believes age-related low-grade chronic inflammation is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong director, officer: Chief Executive Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam officer: Chief Financial Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers officer: SVP of Business Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene director C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao officer: VP of Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode officer: See Remarks C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd. 10 percent owner 16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057

HCW Biologics (HCW Biologics) Headlines

From GuruFocus